AbbVie (ABBV)
(Delayed Data from NYSE)
$197.44 USD
-0.11 (-0.06%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $197.40 -0.04 (-0.02%) 6:12 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$197.44 USD
-0.11 (-0.06%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $197.40 -0.04 (-0.02%) 6:12 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar
by Zacks Equity Research
Mylan (MYL) is partnering with Fujifilm Kyowa to commercialize a biosimilar to Humira (adalimumab).
J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.
FDA Prolongs Review Date for AbbVie Endometriosis Candidate
by Zacks Equity Research
The FDA extends the review period of NDA for AbbVie (ABBV) and partner Neurocrine Biosciences' endometriosis candidate, elagolix, by three months to third-quarter 2018.
Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis
by Zacks Equity Research
The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.
AbbVie's RA Candidate Meets Primary Endpoints in Phase III
by Zacks Equity Research
AbbVie's (ABBV) rheumatoid arthritis candidate, upadacitinib, meets both primary and secondary endpoints in the fourth phase III SELECT study for the given indication.
Biogen Cracks the Case With AbbVie for Humira Biosimilar
by Zacks Equity Research
Biogen (BIIB) and partner Samsung Bioepis resolve an ongoing patent row with AbbVie regarding Biogen's biosimilar version of AbbVie's arthritis drug, Humira, in the EU.
Aeglea Initiates Lung Cancer Combination Study With Keytruda
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) doses first patients in two early stage lung cancer studies evaluating pegzilarginase as single agent and in combination with Merck's Keytruda.
The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer
Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus
by Zacks Equity Research
Novartis' (NVS) Tasigna and Seattle Genetics' (SGEN) Adcetris receive regulatory approvals for label expansion. Pfizer's label expansion application for Xtandi gets priority review.
AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome
by Zacks Equity Research
AbbVie's (ABBV) key lung cancer candidate, Rova-T falls short in a phase II study. AbbVie will not seek accelerated approval of Rova-T in the third-line setting
Why Is AbbVie (ABBV) Stock Crashing Today?
by Ryan McQueeney
Shares of pharmaceutical behemoth AbbVie Inc. (ABBV) dropped more than 11% in early morning trading Thursday after the company???s Rova-T program reported disappointing mid-stage results.
J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit
by Zacks Equity Research
J&J (JNJ) receives an offer for its LifeScan unit from private firm, Platinum Equity. It has time until Jun 15 to accept the offer, failing which it will expire.
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene
Why Multiple Sclerosis is a Promising but Risky Space?
by Zacks Equity Research
Multiple Sclerosis (MS) is a promising space but risks continue to persist with the recent withdrawal of Zinbryta.
Zacks Market Edge Highlights: Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties and AbbVie
by Zacks Equity Research
Zacks Market Edge Highlights: Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties and AbbVie
AbbVie's Uterine Fibroids Candidate Succeeds in Phase III
by Zacks Equity Research
AbbVie (ABBV) and partner Neurocrine Biosciences announce that the second of the two pivotal phase III studies evaluating elagolix, met the primary endpoint for treating women with uterine fibroids.
The Best Marijuana Stocks Right Now
by Tracey Ryniec
It is getting easier to buy stocks that do business in the emerging cannibis industry. Tracey and Dave explore all the options.
Zacks Value Investor Highlights: Diageo, Mylan, Sony, AbbVie and Walgreens
by Zacks Equity Research
Zacks Value Investor Highlights: Diageo, Mylan, Sony, AbbVie and Walgreens
Want to be a Buy and Hold Investor? 3 Strategies
by Tracey Ryniec
It takes more than guts to hold a stock for 40 or 50 years in a portfolio. What lessons can be learned from those who have done it?
Want to be a Buy and Hold Investor? 3 Strategies
by Tracey Ryniec
It takes more than guts to hold a stock for 40 or 50 years in a portfolio. What lessons can be learned from those who have done it?
Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta
by Zacks Equity Research
The biotech sector was in focus last week with these stories - FDA's acceptance of Regeneron's Dupixent's application for asthma, Biogen and partner AbbVie's decision to withdraw multiple sclerosis drug among others.
Profit From Share Buyback Boom With These ETFs
by Sweta Killa
2018 is expected to be the second-busiest year for buybacks since the bull market began in 2009 buoyed by the new tax law.
Gilead Announces Positive Data on New HIV Therapy Biktarvy
by Zacks Equity Research
Gilead (GILD) announces encouraging data from a phase III study, on its new HIV therapy, Biktarvy, at the 2018 Conference on Retroviruses and Opportunistic Infections in Boston.
4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio
by Zacks Equity Research
Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.
Pfizer Gets Mixed Feedback on Cancer Treatments From CHMP
by Zacks Equity Research
CHMP recommends in favor of two hematology medicines of Pfizer (PFE) while recommending against label expansion of kidney cancer drug, Sutent.